Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E. Gramming

Phase 1/2a Clinical Trials of Bi-1206, a Monoclonal Antibody to Fcγriib, Administered as a Single Agent or in Combination With Rituximab in Subjects With B-Cell Malignancies

Hematological Oncology

English

Related publications

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination With Bevacizumab in Patients With Advanced Solid Malignancies

Clinical Cancer Research

Cancer Research

Oncology

2014

English

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

Journal for ImmunoTherapy of Cancer

English

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2010

English

Phase I Study of the Anti Insulin-Like Growth Factor 1 Receptor (IGF-1R) Monoclonal Antibody, AVE1642, as Single Agent and in Combination With Bortezomib in Patients With Relapsed Multiple Myeloma

English

Tolerability of Obinutuzumab Therapy in Patients With Rituximab-Relapsed/Refractory B-Cell Malignancies - A Retrospective Single Center Cohort Study

Oncotarget

Oncology

2018

English

Anti-Tumor Effect of a Novel Soluble Recombinant Human Endostatin: Administered as a Single Agent or in Combination With Chemotherapy Agents in Mouse Tumor Models

PLoS ONE

Multidisciplinary

2014

English

A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

British Journal of Haematology

Hematology

2016

English

Safety Profile and Clinical Activity of Multiple Subcutaneous Doses of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody, in Two Randomized Phase 2a Studies in Subjects With Asthma

BMC Pulmonary Medicine

Pulmonary

Respiratory Medicine

2011

English

MA04.01 Cemiplimab, a Human Monoclonal Anti-Pd-1, Alone or in Combination With Radiotherapy: Phase 1 NSCLC Expansion Cohorts

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E. Gramming

Phase 1/2a Clinical Trials of Bi-1206, a Monoclonal Antibody to Fcγriib, Administered as a Single Agent or in Combination With Rituximab in Subjects With B-Cell Malignancies

Related publications

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination With Bevacizumab in Patients With Advanced Solid Malignancies

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

Phase I Study of the Anti Insulin-Like Growth Factor 1 Receptor (IGF-1R) Monoclonal Antibody, AVE1642, as Single Agent and in Combination With Bortezomib in Patients With Relapsed Multiple Myeloma

Tolerability of Obinutuzumab Therapy in Patients With Rituximab-Relapsed/Refractory B-Cell Malignancies - A Retrospective Single Center Cohort Study

Anti-Tumor Effect of a Novel Soluble Recombinant Human Endostatin: Administered as a Single Agent or in Combination With Chemotherapy Agents in Mouse Tumor Models

A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Safety Profile and Clinical Activity of Multiple Subcutaneous Doses of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody, in Two Randomized Phase 2a Studies in Subjects With Asthma

MA04.01 Cemiplimab, a Human Monoclonal Anti-Pd-1, Alone or in Combination With Radiotherapy: Phase 1 NSCLC Expansion Cohorts